The JAK inhibitor tofacitinib for active rheumatoid arthritis: Results from Phase III trials

International Journal of Clinical Rheumatology

Volumn 8, Issue 3, 2013, Pages 315-326

  Salgado, Eva ^a   Gómez Reino, Juan J ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

CP 690,55; JAK; ORAL trials; protein kinase inhibitor; rheumatoid arthritis; tofacitinib

Indexed keywords

ADALIMUMAB; ASP 015K; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLPG 0634; INFLIXIMAB; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; METHOTREXATE; PLACEBO; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VX 509;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEART ARREST; HERPES ZOSTER; HUMAN; INFECTION; LUNG EMBOLISM; LUNG TUBERCULOSIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS PLEURISY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84879614136     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.13.26     Document Type: Article

References (44)

1. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164), 1568-1573 (1999). (Pubitemid 29219206)
2. Puolakka K, Kautiainen H, Mottonen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 52(1), 36-41 (2005). (Pubitemid 40129230)
3. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004). (Pubitemid 38942816)
4. Goekoop-Ruiterman Y, de Vries-Bouwstra J, Allaart C et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005). (Pubitemid 41612204)
5. Verstappen S, Jacobs J, van der Veen M et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66(11), 1443-1449 (2007). (Pubitemid 350032650)
6. Hetland M, Stengaard-Pedersen K, Junker P et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann. Rheum. Dis. 67(6), 815-822 (2008). (Pubitemid 351829382)
7. Barton J. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 3, 335-344 (2009).
8. Riese R, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract. Res. Clin. Rheumatol. 24(4), 513-526 (2010).
9. Li X, Jesson M, Lee J et al. Characterization of a potent inhibitor of JAK kinases, CP-690,550, and inhibition of specific JAK/STAT pathways at efficacious exposures in a rodent model of arthritis. Presented at: 15th International Inflammation Research Association Conference. Chantilly, VA, USA (2008).
10. Zhu T, Kazuo O, Valluri U et al. Coadministration of ASP015K, a novel janus kinase inhibitor with methotrexate demonstrates tolerability and lack of pharmacokinetic interactions in patients with rheumatoid arthritis. Arthritis Rheum. 64(Suppl. 10), S569 (2012).
11. Garber K. Pfizer's JAK inhibitor sails through Phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29(6), 467-468 (2011).
12. Kremer J, Bloom B, Breedveld F et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009).
13. Fleischmann R, Cutolo M, Genovese M et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumabmonotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum. 64(3), 617-629 (2011).
14. Kremer J, Cohen S, Wilkinson B et al. A Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 64(4), 970-981 (2011).
15. Takeuchi T, Tanaka Y, Yamanaka H et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, as monotherapy in patients with active rheumatoid arthritis: a comparison between Japanese and global populations over 12 weeks of dosing in Phase 2b Studies. Arthritis Rheum. 63(Suppl. 10), 1213 (2011).
16. Tanaka Y, Takeuchi T, Yamanaka H et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week Phase 2b study. Arthritis Rheum. 63(Suppl. 10), 2192 (2011).
17. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich S. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. (Hoboken) 63(8), 1150-1158 (2011).
18. Burmester G, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised Phase 3 trial. Lancet 381(9865), 451-460 (2013).
19. van Vollenhoven R, Flesichmann R, Cohen S et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a Phase 3 study. Arthritis Rheum. 63(Suppl. 10), S153 (2011).
20. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural patients with rheumatoid arthritis: a 24-month Phase 3 study. Arthritis Rheum. 63(Suppl. 10), S1017 (2011).
21. Fleischmann R, Kremer J, Connell C et al. ORAL Solo (A3921045): a Phase 3 study of oral JAK inhibitor tofacitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis: subgroup analysis of efficacy. Ann. Rheum. Dis. 70(Suppl. 3), 600 (2011).
22. Strand V, Kanik K, Connell C et al. ORAL Solo (A3921045): effects of the oral JAK inhibitor tofacitinib (CP-690,550) monotherapy on patient reported outcomes in a Phase 3 study of active rheumatoid arthritis. Ann. Rheum. Dis. 70(Suppl. 3), 88 (2011).
23. Strand V, Kremer J, Li Z et al. Tofacitinib (CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: Phase 3 study patient-reported outcomes in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs. Arthritis Rheum. 63(Suppl. 10), S1032 (2011).
24. Kremer J, Li Z, Hall S et al. Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDS: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDS. Ann. Rheum. Dis. 70(Suppl. 3), 170 (2011).
25. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367(6), 495-507 (2012).
26. van Vollenhoven R, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367(6), 508-519(2012).
27. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month Phase III randomized radiographic study. Arthritis Rheum. 65(3), 559-570 (2013).
28. Connell C, Silverfield J, Forejtova S et al. Long-term follow-up of patients (pts) with moderate to severe rheumatoid arthritis (RA) treated with the oral JAK inhibitor CP-690,550 (CP). Ann. Rheum. Dis. 68(Suppl. 3), 131 (2009).
29. Yamanaka H, Tanaka Y, Takeuchi T et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, as monotherapy or with background methotrexate in japanese patients with rheumatoid arthritis: a Phase 2/3 long-term extension study. Arthritis Rheum. 63(Suppl. 10), S473 (2011).
30. Wollenhaupt J, Silverfield J, Lee E et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months. Arthritis Rheum. 63(Suppl. 10), S152 (2011).
31. Cohen S, Radominski S, Asavatanabodee P et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor: analysis of infections and all-cause mortality across Phase 3 and long-term extension studies in patients with rheumatoid arthritis. Arthritis Rheum. 63(Suppl. 10), S153 (2011).
32. Cohen S, Krishnaswami S, Benda B et al. Tofacitinib, an oral janus kinase inhibitor: analyses of efficacy and safety of 10 versus 5mg twice daily in a pooled Phase 3 and long-term extension rheumatoid arthritis population. Arthritis Rheum. 64(Suppl. 10), 2485 (2012).
33. van Vollenhoven R, Krishnaswami S, Benda B et al. Tofacitinib and adalimumab achieve similar rates of low disease activity in rheumatoid arthritis lack of improvement in disease activity score by 3 months predicts low likelihood of low disease activity at 1 year. Arthritis Rheum. 64(Suppl. 10), 1297 (2012).
34. van der Heijde D, Tanaka, Y, Fleischmann, R et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month Phase 3 study. Arthritis Rheum. 63(Suppl. 10), 2592 (2011).
35. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib, an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: year 2 efficacy and safety results from a 24-month Phase 3 study. Arthritis Rheum. 64(Suppl. 10), 1277 (2012).
36. van der Heijde D, Landewe R, Gruben D. Tofacitinib inhibits radiographic progression in patients with rheumatoid arthritis prone to develop structural damage: a post-hoc analysis of a Phase 3 trial. Arthritis Rheum. 64(Suppl. 10), 2546 (2012).
37. Lee E, Fleischmann R, Hall S et al. Radiographic, clinical and functional comparison of tofacitinib monotherapy versus methotrexate in methotrexate-naive patients with rheumatoid arthritis. Arthritis Rheum. 64(Suppl. 10), S1049 (2012).
38. Ahadieh S, Checchio T, Tensfeldt T et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. Arthritis Rheum. 64(Suppl. 10), 1697 (2012).
39. Winthrop K, Park S, Gul A et al. Tuberculosis and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 64(Suppl. 10), 1278 (2012).
40. Winthrop K, Valdez H, Mortensen E et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 64(Suppl. 10), 2490 (2012).
41. Mariette X, Curtis J, Lee E et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical programme. Ann. Rheum. Dis. 71(Suppl. 3), 199 (2012).
42. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid C, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 20(2), 119-130 (2011).
43. Charles-Schoeman C, Wicker P, Sechtem U et al. Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel oral JAK inhibitor. Ann. Rheum. Dis. 71(Suppl. 3), 201 (2012).
44. Lee EB, Curtis JR, Riese R et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor: analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme. Ann. Rheum. Dis. 71(Suppl. 3), 202 (2012).